GeoVax Labs, Inc. (GOVX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GOVX
- Company GeoVax Labs, Inc.
- Price $2.21
- Changes Percentage 79.67
- Change 0.98
- Day Low $1.78
- Day High $4.39
- Year High $34.75
- Year Low $0.96
- Market Cap $2,118,216
- Price Avg 50 EMA (D) $1.4
- Price Avg 200 EMA (D) $8.16
- Exchange NASDAQ
- Volume 208,001,749
- Average Volume 3,634,868
- Open $3.03
- Previous Close $1.23
- EPS -13.82
- PE -0.16
- Earnings Announcement 2026-07-27 04:00:00
- Shares Outstanding $958,469
Company brief: GEOVAX LABS, INC. (GOVX )
- Healthcare
- Biotechnology
- Mr. David Alan Dodd
- https://www.geovax.com
- US
- N/A
- 09-25-2020
- US3736786068
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GOVX Corporation News
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
zacks.com -- GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....